The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed on Thursday, dampening expectations for the closely watched drug.
A draft summary went online briefly on the WHO Web site and was first reported by the Financial Times and health news Web site Stat, which posted a screenshot.
However, Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying that the data showed a “potential benefit.”
Photo: AFP
The Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group, the summary said, adding that remdesivir was stopped early in 18 patients because of side effects.
The authors said that remdesivir was “not associated with a difference in time to clinical improvement” compared with the control.
After a month, 13.9 percent of the patients on remdesivir had died, compared with 12.8 percent of those in the control group. The difference is not statistically significant.
The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.
“We believe the post included inappropriate characterizations of the study,” a Gilead spokesman told reporters, adding that it was terminated early due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman said.
The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.
Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it.
Last week, Stat reported that it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated.
The US National Institutes of Health also reported it that had proven effective in a small experiment on monkeys.
Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly — as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA, and gets absorbed into the virus’ genome, which in turn stops the pathogen from replicating.
Anti-malarial drugs hydroxychloroquine and chloroquine have also been widely used on COVID-19 on a so-called “compassionate basis” pending results from large trials, with early studies decidedly mixed.
Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically engineered mice that were deliberately infected.
Separately in France, new research shows that nicotine could protect people from contracting COVID-19.
The findings came after researchers at a top Paris hospital examined 343 COVID-19 patients, as well as 139 people with the illness who had milder symptoms.
They found that a low number of them smoked, compared with smoking rates of about 35 percent in France’s general population.
“Among these patients, only 5 percent were smokers,” said Zahir Amoura, the study’s coauthor and a professor of internal medicine.
The research echoed similar findings published in the New England Journal of Medicine last month suggesting that 12.6 percent of 1,000 people infected in China were smokers.
That was a much lower figure than the number of regular smokers in China’s general population, about 26 percent, WHO data showed.
The theory is that nicotine could adhere to cell receptors, therefore blocking the novel coronavirus from entering cells and spreading in the body, said neurobiologist Jean-Pierre Changeux from France’s Pasteur Institute, who also coauthored the study.
The researchers are awaiting approval from health authorities to carry out further clinical trials.
The researchers are looking into whether nicotine could help to prevent “cytokine storms,” a rapid overreaction of the immune system that scientists think could play a key role in fatal COVID-19 cases.
However, with further research needed, experts are not encouraging people to pick up smoking or use nicotine patches as a protective measure against the virus.
“We must not forget the harmful effects of nicotine,” French Director-General for Health Jerome Salomon said.
“Those who do not smoke should absolutely not use nicotine substitutes,” which cause side effects and addiction, he said.
DEADLOCK: Putin has vowed to continue fighting unless Ukraine cedes more land, while talks have been paused with no immediate results expected, the Kremlin said Russia on Friday said that peace talks with Kyiv were on “pause” as Ukrainian President Volodymyr Zelenskiy warned that Russian President Vladimir Putin still wanted to capture the whole of Ukraine. Meanwhile, US President Donald Trump said that he was running out of patience with Putin, and the NATO alliance said it would bolster its eastern front after Russian drones were shot down in Polish airspace this week. The latest blow to faltering diplomacy came as Russia’s army staged major military drills with its key ally Belarus. Despite Trump forcing the warring sides to hold direct talks and hosting Putin in Alaska, there
North Korea has executed people for watching or distributing foreign television shows, including popular South Korean dramas, as part of an intensifying crackdown on personal freedoms, a UN human rights report said on Friday. Surveillance has grown more pervasive since 2014 with the help of new technologies, while punishments have become harsher — including the introduction of the death penalty for offences such as sharing foreign TV dramas, the report said. The curbs make North Korea the most restrictive country in the world, said the 14-page UN report, which was based on interviews with more than 300 witnesses and victims who had
COMFORT WOMEN CLASH: Japan has strongly rejected South Korean court rulings ordering the government to provide reparations to Korean victims of sexual slavery The Japanese government yesterday defended its stance on wartime sexual slavery and described South Korean court rulings ordering Japanese compensation as violations of international law, after UN investigators criticized Tokyo for failing to ensure truth-finding and reparations for the victims. In its own response to UN human rights rapporteurs, South Korea called on Japan to “squarely face up to our painful history” and cited how Tokyo’s refusal to comply with court orders have denied the victims payment. The statements underscored how the two Asian US allies still hold key differences on the issue, even as they pause their on-and-off disputes over historical
CONSOLIDATION: The Indonesian president has used the moment to replace figures from former president Jokowi’s tenure with loyal allies In removing Indonesia’s finance minister and U-turning on protester demands, the leader of Southeast Asia’s biggest economy is scrambling to restore public trust while seizing a chance to install loyalists after deadly riots last month, experts say. Demonstrations that were sparked by low wages, unemployment and anger over lawmakers’ lavish perks grew after footage spread of a paramilitary police vehicle running over a delivery motorcycle driver. The ensuing riots, which rights groups say left at least 10 dead and hundreds detained, were the biggest of Indonesian President Prabowo Subianto’s term, and the ex-general is now calling on the public to restore their
RSS